<DOC>
	<DOCNO>NCT02672358</DOCNO>
	<brief_summary>This open-label , multicenter , non-randomized , single arm , phase II study ass efficacy safety dabrafenib trametinib combination Japanese patient line , stage IV NSCLC harbor confirm BRAF V600E mutation . Patients receive oral dabrafenib twice daily oral trametinib daily combination therapy . Patients may continue study treatment disease progression , unacceptable adverse event , start new anti-cancer therapy , consent withdrawal , death , end study . Patients meet criteria disease progression ( PD ) accord RECIST v1.1 may continue receive study treatment investigator believe patient receive clinical benefit patient willing continue study treatment . After discontinuation study treatment , patient follow survival death , lose follow-up , withdrawal consent , end study .</brief_summary>
	<brief_title>Study Efficacy Safety Dabrafenib Trametinib Combination Therapy Japanese Patients With BRAF V600E Stage IV NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Histologically cytologicallyconfirmed diagnosis NSCLC stage IV ( accord AJCC Staging 7th Edition ) Presence BRAF V600E mutation lung cancer tissue . BRAF V600E mutation test local laboratory ( e.g . study center laboratory , local laboratory company ) proper quality control license operation local health authority allow . Measurable disease accord RECIST v1.1 . Previous treatment BRAF inhibitor ( include limit dabrafenib , vemurafenib , encorafenib , XL281/BMS908662 ) MEK inhibitor ( include limit trametinib , cobimetinib , binimetinib , AZD6244 , RDEA119 ) prior start study treatment Patients brain metastasis exclude brain metastasis : Symptomatic OR Treated ( surgery , radiation therapy ) clinically radiographically stable 3 week local therapy ( assess contrast enhance magnetic resonance image [ MRI ] compute tomography [ CT ] ) , OR Asymptomatic untreated &gt; 1 cm long dimension History malignancy confirm activate RAS mutation time . History interstitial lung disease pneumonitis A history current evidence retinal vein occlusion ( RVO ) Current evidence unstable aneurysm one need treatment Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>trametinib</keyword>
	<keyword>Japanese patient</keyword>
	<keyword>BRAF V600E mutation positive metastatic</keyword>
	<keyword>stage IV</keyword>
</DOC>